Urinary Luteinizing Hormone Tests: Which Concentration Threshold Best Predicts Ovulation?

Rene Antonio Leiva, Thomas Paul Bouchard, Saman Hasan Abdullah, René Ecochard, Rene Antonio Leiva, Thomas Paul Bouchard, Saman Hasan Abdullah, René Ecochard

Abstract

Objective: To study the best possible luteinizing hormone (LH) threshold to predict ovulation within the 24, 48, and 72 h.

Design: Observational study.

Setting: Multicenter collaborative study.

Patients: A total of 107 women.

Interventions: Women collected daily first morning urine for hormonal assessment and underwent serial ovarian ultrasound. This is a secondary analysis of 283 cycles.

Main outcome measures: The sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were estimated for varying ranges of LH thresholds. Receiver operating characteristic curves and cost-benefit ratios were used to estimate the best thresholds to predict ovulation.

Results: The best scenario to predict ovulation at random was within 24 h after the first single positive test. The false-positive rate was found to increase as (1) the cycle progressed or (2) two or three consecutive tests were used, or (3) ovulation was predicted within 48 or 72 h. Testing earlier in the cycle increases the predictive value of the test. The ideal thresholds to predict ovulation ranged between 25 and 30 mIU/ml with a PPV (50-60%), NPV (98%), LR+ (20-30), and LR- (0.5). At least, one day with LH ≥25 mIU/ml followed by three negatives (LH <25) occurred before ovulation in 31% of all cycles. When used throughout the cycle and evaluated together, peak-fertility type mucus with a positive LH test ≥25 mIU/ml provides a higher specificity than either mucus or LH testing alone (97-99 vs. 77-95 vs. 91%, respectively).

Conclusion: We identified that beginning LH testing earlier in the cycle (day 7) with a threshold of 25-30 mIU/ml may present the best predictive value for ovulation within 24 h. However, prediction by LH testing alone may be affected negatively by several confounding factors so LH testing alone should not be used to define the end of the fertile window. Complementary markers should be further investigated to predict ovulation and identify the fertile window. The use of the peak cervical mucus along with an LH test may provide a higher specificity and predictive value than either of them alone. We recommend that manufacturers disclose their tests' threshold to the public.

Keywords: fertile window; fertility awareness methods; infertility; luteinizing hormone; natural family planning; ovulation; ovulation predictor kits; urine.

Figures

Figure 1
Figure 1
Number of ovulations (N) across the days of the menstrual cycle.
Figure 2
Figure 2
Nine ovulation predictive scenarios for the proportion of true-positive rates to false-positive rates from days 9 to 17 of the cycles.
Figure 3
Figure 3
The receiver operating characteristic curves for one random positive luteinizing hormone test to predict ovulation within 24 h-across the menstrual cycle.
Figure 4
Figure 4
The receiver operating characteristic curves for one random positive luteinizing hormone (LH) test to predict ovulation within 24 h-across the menstrual cycle, applying different ranges on the number of daily tests used.
Figure 5
Figure 5
Number of cycles with one positive day [luteinizing hormone (LH) threshold ≥25 mlU/ml] followed by three consecutive negative days (LH thresholds ≤25 mlU/ml) in relation to ultrasound day of ovulation (0 US-DO).

References

    1. Yong EL, Wong PC, Kumar A, Wong YC, Goh HH, Hagglund L, et al. Simple office methods to predict ovulation: the clinical usefulness of a new urine luteinizing hormone kit compared to basal body temperature, cervical mucus and ultrasound. Aust N Z J Obstet Gynaecol (1989) 29(2):155–60.10.1111/j.1479-828X.1989.tb01707.x
    1. Leiva R, Burhan U, Kyrillos E, Fehring R, McLaren R, Dalzell C, et al. Use of ovulation predictor kits as adjuncts when using fertility awareness methods (FAMs): a pilot study. J Am Board Fam Med (2014) 27(3):427–9.10.3122/jabfm.2014.03.130255
    1. Eichner SF, Timpe EM. Urinary-based ovulation and pregnancy: point-of-care testing. Ann Pharmacother (2004) 38(2):325–31.10.1345/aph.1D210
    1. Direito A, Bailly S, Mariani A, Ecochard R. Relationships between the luteinizing hormone surge and other characteristics of the menstrual cycle in normally ovulating women. Fertil Steril (2013) 99(1):279–85.10.1016/j.fertnstert.2012.08.047
    1. Park SJ, Goldsmith LT, Skurnick JH, Wojtczuk A, Weiss G. Characteristics of the urinary luteinizing hormone surge in young ovulatory women. Fertil Steril (2007) 88(3):684–90.10.1016/j.fertnstert.2007.01.045
    1. Alliende ME. Mean versus individual hormonal profiles in the menstrual cycle. Fertil Steril (2002) 78:1.10.1016/S0015-0282(02)03167-9
    1. Nielsen MS, Barton SD, Hatasaka HH, Stanford JB. Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril (2001) 76(2):384–7.10.1016/S0015-0282(01)01881-7
    1. When the test really counts: part two: the fertility window. Consum Rep (2003) 68(2):48–50.
    1. Ghazeeri GS, Vongprachanh P, Kutteh WH. The predictive value of five different urinary LH kits in detecting the LH surge in regularly menstruating women. Int J Fertil Womens Med (2000) 45(5):321–6.
    1. Ecochard R, Leiva R, Bouchard T, Boehringer H, Direito A, Mariani A, et al. Use of urinary pregnanediol 3-glucuronide to confirm ovulation. Steroids (2013) 78(10):1035–40.10.1016/j.steroids.2013.06.006
    1. Ecochard R, Boehringer H, Rabilloud M, Marret H. Chronological aspects of ultrasonic, hormonal, and other indirect indices of ovulation. BJOG (2001) 108(8):822–9.10.1111/j.1471-0528.2001.00194.x
    1. Ecochard R, Marret H, Rabilloud M, Bradaï R, Boehringer H, Girotto S, et al. Sensitivity and specificity of ultrasound indices of ovulation in spontaneous cycles. Eur J Obstet Gynecol Reprod Biol (2000) 91(1):59–64.10.1016/S0301-2115(99)00249-3
    1. Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat (2008) 62(4):314–20.10.1198/000313008X370302
    1. Vránová J, Horák J, Krátká K, Hendrichová M, Kovaírková K. [Receiver operating characteristic analysis and the cost – benefit analysis in determination of the optimal cut-off point]. Cas Lek Cesk (2009) 148(9):410–5.
    1. Ecochard R, Duterque O, Leiva R, Bouchard T, Vigil P. Self-identification of the clinical fertile window and the ovulation period. Fertil Steril (2015) 103(5):1319–25.e3.10.1016/j.fertnstert.2015.01.031
    1. Johnson S, Weddell S, Godbert S, Freundl G, Roos J, Gnoth C. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day. Clin Chem Lab Med (2015) 53(7):1099–108.10.1515/cclm-2014-1087
    1. Evans-Hoeker E, Pritchard DA, Long DL, Herring AH, Stanford JB, Steiner AZ. Cervical mucus monitoring prevalence and associated fecundability in women trying to conceive. Fertil Steril (2013) 100(4):1033–8.10.1016/j.fertnstert.2013.06.002
    1. Freundl G, Frank-Herrmann P, Brown S, Blackwell L. A new method to detect significant basal body temperature changes during a woman’s menstrual cycle. Eur J Contracept Reprod Health Care (2014) 19(5):392–400.10.3109/13625187.2014.948612
    1. Blackwell LF, Vigil P, Alliende ME, Brown S, Festin M, Cooke DG. Monitoring of ovarian activity by measurement of urinary excretion rates using the Ovarian Monitor, Part IV: the relationship of the pregnanediol glucuronide threshold to basal body temperature and cervical mucus as markers for the beginning of the post-ovulatory infertile period. Hum Reprod (2016) 31(2):445–53.10.1093/humrep/dev303
    1. Fehring RJ, Schneider M, Raviele K, Rodriguez D, Pruszynski J. Randomized comparison of two Internet-supported fertility-awareness-based methods of family planning. Contraception (2013) 88(1):24–30.10.1016/j.contraception.2012.10.010
    1. Nichols JH, Christenson RH, Clarke W, Gronowski A, Hammett-Stabler CA, Jacobs E, et al. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta (2007) 379(1–2):14–28; discussion 29–30.10.1016/j.cca.2006.12.025

Source: PubMed

3
Prenumerera